$AGPU

Stock Analysts’ Downgrades for June 21st (AGPU, ALNY, AMX, ATPC, BNKK, CLBK, CPT, CTRN, DVN, ESS)

Wall Street Zen downgraded multiple stocks on June 21, including Predictive Oncology (AGPU) to sell from hold, Agape ATP (ATPC) to sell from hold, Bonk (BNKK) to sell from hold, Columbia Financial (CLBK) to sell from hold, and Camden Property Trust (CPT) to sell from hold. It also cut several ratings to hold or buy for companies such as Devon Energy (DVN), fuboTV (FUBO), and Alnylam (ALNY).

Original reporting
Published Jun 21, 2026, 5:45 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 21, 2026, 6:32 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Stock Analysts’ Downgrades for June 21st (AGPU, ALNY, AMX, ATPC, BNKK, CLBK, CPT, CTRN, DVN, ESS) — source image
Decision brief

The 30-second read

$AGPUBearishLow
01

Why it matters

Each listed company experienced a downgrade (mostly toward Sell or Hold), which can affect near-term sentiment and positioning, but the article lacks the underlying rationale or price targets.

02

Market read

This is a sentiment-driven, multi-ticker downgrade list; it may influence Monday open trading but provides no new fundamental datapoints.

03

What to watch

Traders should check whether these are first-time or follow-on downgrades, and whether other firms issued concurrent changes—this text doesn’t include that context.

Relevance 4/10Novelty 3/10Timing: after-hours / end-of-day Sunday watch for Monday open reactions

Background

The piece is a multi-name roundup of analyst rating changes attributed to Wall Street Zen for Sunday, June 21.

Company-level read

Ticker impact

$AGPUBearishMedium confidence
Context

Predictive Oncology (AGPU) was downgraded from Hold to Sell by Wall Street Zen, shifting analyst stance toward downside risk.

Expected impact

Likely negative bias for the next session(s), with magnitude depending on AGPU’s liquidity and prior positioning.

Evidence & confidence

The article provides only the rating change (no PT/earnings details), but rating downgrades often move short-term flows.

$ALNYNeutralMedium confidence
Context

Alnylam (ALNY) was downgraded from Strong Buy to Buy, a modest de-risking of the prior bullish view.

Expected impact

Mildly negative to neutral near-term, unless the market had already priced the prior Strong Buy.

Evidence & confidence

No price target or thesis details are provided; the action is still a sentiment headwind.

$AMXNeutralMedium confidence
Context

America Movil (AMX) was downgraded from Strong Buy to Buy, trimming the analyst’s conviction level.

Expected impact

Slight negative/neutral impact, more likely if AMX was trading on aggressive buy-side expectations.

Evidence & confidence

The downgrade is real but lacks accompanying fundamental catalysts in the text.

$ATPCBearishMedium confidence
Context

Agape ATP (ATPC) was downgraded from Hold to Sell, increasing perceived downside risk.

Expected impact

Negative bias for the next session(s), especially if ATPC is thinly traded.

Evidence & confidence

Rating change is the only disclosed fact; without PT/thesis, impact is uncertain but directionally negative.

$BNKKBearishMedium confidence
Context

Bonk (BNKK) was downgraded from Hold to Sell, moving the call toward bearish positioning.

Expected impact

Negative near-term bias; magnitude depends on BNKK’s trading liquidity.

Evidence & confidence

No additional fundamentals are provided beyond the rating shift.

$CLBKBearishMedium confidence
Context

Columbia Financial (CLBK) was downgraded from Hold to Sell, signaling higher risk or weaker outlook.

Expected impact

Likely negative near-term reaction, though size is uncertain without PT details.

Evidence & confidence

The article contains only the rating change; still, Hold-to-Sell is directionally meaningful.

$CPTBearishMedium confidence
Context

Camden Property Trust (CPT) was downgraded from Hold to Sell, reducing bullish expectations for the REIT.

Expected impact

Negative bias for the next session(s), especially if CPT had been supported by prior Hold ratings.

Evidence & confidence

No thesis or valuation metrics are included; impact likely sentiment-driven.

$CTRNNeutralMedium confidence
Context

Citi Trends (CTRN) was downgraded from Buy to Hold, tempering upside expectations.

Expected impact

Slight negative to neutral near-term.

Evidence & confidence

Buy-to-Hold is a mild de-risking; without PT/thesis, confidence is limited.

Market effects

Multiple downgrades across REITs, energy, biotech, and consumer names suggest a risk-off tilt from analyst sentiment rather than a single-sector catalyst.

Primarily US-listed equities; no cross-market macro/regulatory trigger cited.

Limited—no global deal, regulation, or commodity shock described; impacts are stock-specific sentiment.

Counterpoint

Because the article provides only rating changes (no PTs/thesis), price moves may fade if fundamentals haven’t changed.

Key entities

  • Wall Street Zen

    Source attributed for the rating changes in the article.

Related articles

$MRNAMedAI 8/10

What’s in Merck and Moderna’s cancer vaccine algorithm?

Moderna is raising $2 billion in convertible debt following the success of its personalized cancer vaccine developed with Merck. The vaccine uses an algorithm to analyze tumor mutations and create a bespoke mRNA treatment. Some investors question the necessity of personalization. Meanwhile, a U.S. biotech crackdown on China could benefit European companies, and a rival drug failure may impact Alnylam's ATTR-CM franchise.

$ALNYMedAI 8/10

Vutrisiran May Stabilize Right Ventricle Function in ATTR-CM

A post hoc analysis of the HELIOS-B trial found that vutrisiran, developed by Alnylam Pharmaceuticals, stabilized right ventricular function in patients with ATTR-CM, reducing mortality and cardiovascular risks. The study, published in JAMA Cardiology, showed significant improvements in RVFWS and RVFWS/PASP compared to placebo. Funding and disclosures were reported by Alnylam and other healthcare companies.